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Abstract
The association of cardiovascular events with Lp-PLA2 has been studied continuously today. The enzyme has been
strongly associated with several cardiovascular risk markers and events. Its discovery was directly related to the
hydrolysis of the platelet-activating factor and oxidized phospholipids, which are considered protective functions.
However, the hydrolysis of bioactive lipids generates lysophospholipids, compounds that have a pro-inflammatory
function. Therefore, the evaluation of the distribution of Lp-PLA2 in the lipid fractions emphasized the dual role of
the enzyme in the inflammatory process, since the HDL-Lp-PLA2 enzyme contributes to the reduction of
atherosclerosis, while LDL-Lp-PLA2 stimulates this process. Recently, it has been verified that diet components and
drugs can influence the enzyme activity and concentration. Thus, the effects of these treatments on Lp-PLA2 may
represent a new kind of prevention of cardiovascular disease. Therefore, the association of the enzyme with the
traditional assessment of cardiovascular risk may help to predict more accurately these diseases.
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1. Introduction
The physiopathology of cardiovascular disease (CVD) is
marked by the presence of atherosclerosis that involves
endothelial dysfunction, inflammation, oxidative stress,
insulin resistance and dyslipidemia.
Even considering the early diagnosis and the new vari-
ety of treatments for CVD, the American College of
Cardiology still predicts that there will be 25 million
cases only in USA until the end of 2050 [1]. Further-
more, given the current importance of CVD, thanks to
its high worldwide prevalence that accounts for nearly
30% of the global deaths [2], the monitoring of the new
biomarkers and risk factors represents an important
focus of new researches.
In this context, lipoprotein-associated phospholipase
A2 (Lp-PLA2 ) represents a potential cardiovascular risk
marker, given its correlations with coronary disease and
stroke [3-7]. Initially, Lp-PLA2 was recognized by its
action on hydrolyzing platelet-activating factor (PAF);
such characteristic has assigned to it the first name pla-
telet-activating factor acetylhydrolase (PAF-AH) [8].
Despite the other important reviews of Lp-PLA2
[9-11], the question of whether high activity of Lp-PLA2
is a causal event or a result of atherosclerosis remains
open. Therefore, the main goal of this review is to show
the antioxidant and inflammatory role of Lp-PLA2 and
its connection with atherosclerosis, aiming to contribute
to the discussions of atherogenic or anti-atherogenic
role of Lp-PLA2 . We also discuss possible mechanisms
of modulation of Lp-PLA2 .
2. Biochemistry and structural aspects
A brief biological background is necessary to compre-
hend mechanisms enrolling Lp-PLA2 and atherosclerosis.
Platelet-activating factor (PAF) is an active phospholipid
related to many pathologic and physiologic reactions
[12]. The PAF is formed through two reactions (Figure
1). Firstly, the cytosolic phospholipase A2 (cPLA2 ) acts
on membrane phospholipids producing lysophospholi-
pids; then, the lysophospholipids are modified by PAF
acetyltransferase, resulting in the formation of PAF [13].* Correspondence: nagila@usp.br
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Thus, PAF concentration is modulated by Lp-PLA2 activ-
ity [13,14].
Lp-PLA2 was discovered on 1980 and it was classified
as a Ca2+-independent PLA2 [8], produced by a wide
range of inflammatory and non-inflammatory cells
[15-17]. It is considered a member of phospholipases
family (PLA2 ), although exhibits different properties
when compared to other PLA2 [18]. In addition, while
Lp-PLA2 is specific for the breakdown of PAF and oxi-
dized fatty acid residues, PLA2 is specific for phospholi-
pids containing two long chain acyl groups [18-21].
Another feature of Lp-PLA2 is that it shows different
isoforms, though the more common types are distribu-
ted in intracellular [22] and extracellular compartment
[8]. Intracellular Lp-PLA2 shows two variables, I and II
[23], while brain tissue exhibits a subtype named Lp-
PLA2 -Ib [24]. The Lp-PLA2 type II consists of a 40-
KDa polypeptide chain, and has been associated with
antioxidant properties [25]. The extracellular Lp-PLA2 ,
identified as plasma form, circulates in association pri-
marily with LDL (80-85%) and on minor portion with
HDL (15-20%), having its activity strongly correlated
with the cholesterol concentrations [26,27]. Lp-PLA2 has
been extracted from human plasma and erythrocytes,
bovine brain, liver and seminal plasma, guinea pig
peritoneal fluid and plasma, mouse plasma and platelets,
cultured rat Kupffer cell- and hepatocyte-conditioned
media, rat bile and the parasite Nippostrongylus brasi-
liensis [28]. On the same hand, it was verified that the
different isoforms of Lp-PLA2 define distinct activities
for the enzyme [23,29,30].
3. Antioxidant role of Lp-PLA2
The oxidative stress is closely associated with inflamma-
tion and bioactive lipid formation. These bioactive lipids,
such as PAF, PAF-like substances, and oxidized phos-
pholipids, have been identified in atherosclerotic plaque
[31]. PAF-like products are formed when the phospholi-
pids of the cellular membrane suffers oxidative damage,
resulting in compounds that have structures with
shorter peroxidized residues at their second carbon and
that mimic the action of PAF [32].
In presence of oxidized phospholipids, Lp-PLA2
removes these fragments acting as an antioxidant. Mat-
suzawa et al. [33], suggested that the over expression of
Lp-PLA2 protects the cells of reactive oxygen species
(ROS)-induced apoptosis through oxidized phospholi-
pids hydrolysis.
In addition, oxidized LDL and LDL(-) are known to be
important factors on the atherosclerosis initiation and
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Figure 1 Role of Lp-PLA2 on the generation of lysophospholipids.
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development [34-36]. Heery et al. [37] demonstrated
that the formation of oxidized phospholipids in LDL sti-
mulates Lp-PLA2 activity. It is most likely that the Lp-
PLA2 hydrolysis of the lipids present in this particle
represents an important antiatherogenic role. In this
context, Watson et al. [38] showed that the Lp-PLA2 ,
hydrolyzing oxidized phospholipids, minimizes the gen-
eration of highly oxidized LDL, increasing the minimally
oxidized LDL content. Subsequently, Benitez et al. [39]
found that the major portion of Lp-PLA2 was associated
with LDL(-) in detriment to LDL(+), suggesting that the
release of chemotactic induced by LDL(-) could be a
consequence of the high Lp-PLA2 activity. Indeed, LDL
(-) can be generated by Lp-PLA2 , although the origin of
this sub-group of LDL could to be also compatible with
oxidative reaction and other mechanisms such as non
enzymatic glycosylation, changes on Apo E (apolipopro-
tein E) and Apo CII (apolipoprotein CII), non esterified
fat acids (NEFAS) enrichment or cross linking with
hemoglobin [40].
Lourida et al. [41] showed that Lp-PLA2 activity is
important for reducing the immunogenicity of oxLDL, a
phenomenon that can be attributed to the decreasing of
oxidized phospholipids in patients with coronary artery
disease and healthy ones. More recently, Noto et al. [42]
showed in animals that Lp-PLA2 protects lipoproteins
from oxidation, producing less proatherogenic lipopro-
teins and preserving HDL functions. In this direction,
Bazan [43] proposed that recombinant Lp-PLA2 could
be a potential tool directed to antiatherogenic therapy.
4. Inflammatory action of Lp-PLA2
Despite the antioxidant potential described above, the
association of Lp-PLA2 with inflammatory reactions
represents the majority of the studies in literature in the
last years.
When Lp-PLA2 hydrolyzes bioactive lipids, reducing
their biological activity, the most generated metabolites
are the lysophospholipids. These lipids are involved with
atherosclerotic process and show a deleterious role of
Lp-PLA2 , contributing to the inflammatory response
against oxidized lipoproteins [39,44,45]. These com-
pounds generated by phospholipases A2 during cell acti-
vation, injury, or apoptosis, are known to affect the
function of neutrophils and of a diversity of cell types
[46], and can be also produced by phospholipase A1
and by the action of lecithin-cholesterol acyltransferase
(LCAT) or endothelial lipase. There are many different
lysophospholipids, but the main product of Lp-PLA2
action is lysophosphatidylcholine [47]; these metabolic
processes occur in physiological conditions.
Furthermore, lysophospholipids from apoptotic cells
contribute to attract monocytic cells and primary
macrophages [48,49]. In this context, Steinbrecher &
Pritchard [45] showed that oxLDL, on the presence of
phenylmethanesulphonylfluoride (PMSF), an inhibitor of
Lp-PLA2 , has lower values of lysophospholipids. In this
fashion, Muller et al. [50] proposed that lysophosphati-
dylcholine represents a biomarker of the intensity of the
reactive oxygen species production at the inflammatory
site. Accordingly, Lavi et al. [51] found that patients
with early coronary atherosclerosis had higher lysopho-
sphatidylcholine when compared with control subjects.
This profile was confirmed by Herrmann et al. [52],
who showed that carotid artery plaques of patients with
cardiac events presented higher Lp-PLA2 , lysophospho-
lipids, macrophage and collagen content when compared
to patients without events.
Studying the effects of oxLDL, Kuniyasu et al. [53]
demonstrated that oxLDL, and particularly, the lysopho-
sphatidylcholine present in this particle, enhances the
plasminogen activator inhibitor-1 expression. Vickers et
al. [54] demonstrated also that lysophosphatidylcholine
can contribute to calcify vascular cells on the athero-
sclerotic plaque, through up-regulation of osteogenic
genes and proteins. Hence, many events present in
atherosclerotic process involve directly Lp-PLA2 or its
products.
Figure 2 summarizes the possible atherogenic mechan-
isms involving Lp-PLA2 . In this context, there can be
an individual with dyslipidemia, obesity, hypertension,
insulin resistance and oxidative stress, and therefore,
highly prone to atherosclerosis. These factors contribute
initially to the endothelial dysfunction, characterized by
the expression of more adhesion molecules and by lar-
ger spaces between endothelial cells. Thus, the LDL,
macrophages and T lymphocytes can transmigrate more
easily to arterial intima. This LDL particle shows a phe-
notype more atherogenic, being dense and small, char-
acteristics that make it more susceptible to oxidation. In
this site, the reduced content of antioxidants favors the
high production of free radicals, and consequently oxi-
dative modifications of LDL. Thus, the Lp-PLA2 will be
activated by oxidized phospholipids present in OxLDL.
The enzyme minimizes modifications of OxLDL,
hydrolyzing its oxidized phospholipids; this may be
interpreted as an antioxidant action. However, during
this process, there are produced high contents of lyso-
phospholipids and oxidized non esterified fat acids
(OxNEFAS) that promote adhesion molecules expres-
sion and attract macrophages to the arterial intima. The
OxLDL, lysophospholipids and OxNEFAS also stimu-
lates cytokines production, like TNF-a and IL-6, which
increase the inflammatory profile in the region of the
plate. The activated macrophages, through scavenger
receptors, phagocyte OxLDL, gradually turning up in
foam cells. The muscle cells are also attracted, and
migrate to the intima, where they produce collagen,
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elastin and elastases, involving and stabilizing the lipid
plaque. Subsequently, the macrophages become apopto-
tic, as well as the muscle cells, causing released of lipids
in the plaque. In this process, the presence of OxLDL,
as well as lysophospholipids and OxNEFAS produced by
Lp-PLA2, is always stimulating the growth of the plaque;
these are factors that can be decisive to plaque rupture
susceptibility that can culminate in a cardiovascular
event.
5. Lp-PLA2 and Cardiometabolic Risk
Taking into account the mechanisms described, Lp-
PLA2 could influence the cardiometabolic risk; the Fig-
ure 3 expresses the two main possibilities for action of
the enzyme in cardiovascular disease context; the anti-
oxidant action, where these hydrolysis reduce the oxi-
dized phospholipids in plasma and the oxLDL
contributing to generation of LDL(-); the inflammatory
action, where the hydrolysis of PAF, PAF-like products
or oxidized phospholipids generate lysophospholipids
that stimulate inflammation, so the atherogenic process
is stimulated.
According to Campo et al. [55], Lp-PLA2 activity was
significantly associated with LDL-cholesterol in hyperch-
olesterolemic patients. As a matter of fact, dyslipidemia
promotes an increase in plasma Lp-PLA2 activity and
alters the enzyme distribution between apo B- and apo
AI-containing lipoproteins, as observed by Tsimihodi-
mos et al. [56]. The role of LDL-associated Lp-PLA2
remains controversial, possibly because of the difficulty
in analyzing the actions of the enzyme in the dense LDL
particle [57].
On the other hand, studies also have showed that the
enzyme activity associated with HDL particles can play
an antiatherogenic action. Theilmeier et al. [58] demon-
strated by in vitro and in vivo models that HDL-Lp-
PLA2 (HDL-Lipoprotein-associated phospholipase A2 )
activity was linked to reduction of endothelial adhesive-
ness and of macrophage recruitment to lesion prone
sites. Afterwards, the same group demonstrated that
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Figure 2 Possible actions of Lp-PLA2 in the atherosclerotic process.
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atorvastatin induced the increase of HDL-Lp-PLA2
activity and the reduction of LDL-Lp-PLA2 (LDL-Lipo-
protein-associated phospholipase A2 ) activity [56].
Papavasiliou et al. [59], investigating chronic kidney
disease patients, found an increase in plasma Lp-PLA2
activity and a reduction of the ratio of HDL-Lp-PLA2 to
plasma when compared to controls. In the same way,
Rizos et al. [26] demonstrated that patients with meta-
bolic syndrome have higher Lp-PLA2 activity than con-
trols. Nevertheless, the Lp-PLA2 content in HDL was
lower; these results were confirmed by Lagos et al. [60],
who observed that the HDL-Lp-PLA2 activity was lower
in patients with metabolic syndrome. Okamura et al.
[31] suggested that even the Lp-PLA2 having an impor-
tant function in atherogenesis, its association with HDL
plays the opposite role, as observed by high LDL-Lp-
PLA2 to HDL-Lp-PLA2 ratio in patients with atrial
fibrillation.
In this fashion, Noto et al. [61] showed that diabetic
patients with metabolic syndrome have significantly
higher Lp-PLA2 activity than those without this disease,
reflecting its importance to metabolic risk. Following up,
in a cohort with 299 subjects, Allison et al. [62]
demonstrated that an increment of one standard devia-
tion in Lp-PLA2 activity was associated with a higher
risk of CVD in five years, but not with mortality. Kiechl
et al. [63], in a prospective study, demonstrated that
oxidized phospholipids/apo B ratio predicted the cardio-
vascular risk, being the Lp-PLA2 activity an amplifier of
this risk.
Accordingly, Sabatine et al. [4] observed that an ele-
vated level of Lp-PLA2 is a predictor of adverse cardio-
vascular outcomes, independently of the traditional
clinical risk factors in patients with stable coronary
artery disease. Persson et al. [64] observed that this
enzyme was strongly correlated with lipid fractions and
the degree of carotid artery atherosclerosis; this study
showed that the association with cardiovascular risk is
stronger for activity than for mass, reinforcing the
impact of activity in atherogenesis [64].
In a prospective population-based survey, which
occurred between 1990 and 2005, it was verified that
Lp-PLA2 was higher in subjects with incidence of CVD
[5]. In the same year, Jenny et al. [65] showed that sub-
jects with heart failure have the elevation of Lp-PLA2
levels associated with an increase in the mortality risk.
Atherosclerosis
Lp-PLA2
oxLDL PAF 
Lysophospholipids
LDL (-)
 oxidized phospholipids
Antioxidant actionInflammatory action
+
Figure 3 Lp-PLA2 action on cardiovascular disease.
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It was detected also that subjects aged > 65 years pre-
sented an association between the Lp-PLA2 and myocar-
dial infarction [65]. An increasing risk of major adverse
cardiac events associated with elevated Lp-PLA2 was
also observed in community-based cohort of patients
with acute coronary syndrome [6].
More recently, the Lp-PLA2 Studies Collaboration,
analyzing 32 prospective studies, confirmed that the
enzyme activity and mass were related to proatherogenic
lipids and vascular risk [66]. The study showed also that
the association of the enzyme activity with lipid markers
is stronger than the association with mass [66]. Recently,
the authors of this review verified that the Lp-PLA2
activity in adolescents is positively associated with total
cholesterol, LDL-C, insulin, glucose, HOMA-IR, Apo B
(apolipoprotein B)/Apo AI (apolipoprotein AI) ratio and
negatively related to HDL size.
In contrast with the studies above, Tsironis et al. [67]
showed that patients with coronary disease exhibit
reduced LDL-Lp-PLA2 mass and catalytic efficiency,
suggesting a diminished ability to degrade pro-inflam-
matory phospholipids.
Therefore, it is probably that Lp-PLA2 shows a dual
action, directly dependent on its association with LDL
(proatherogenic) or HDL (antiatherogenic). Table 1
summarizes the antioxidant, inflammatory and neutral
links between Lp-PLA2 and cardiometabolic risk.
6. Modulation of Lp-PLA2
Studies focused on Lp-PLA2 modulation are little
explored in literature, despite of its possible manipula-
tion. Regarding that Lp-PLA2 is associated with choles-
terol and oxidized lipids in LDL and HDL, it is probable
that drugs and environment factors, capable of modulat-
ing the lipid metabolism, may change the mass and the
activity of this enzyme.
Gerra et al. [68] showed that lovastatin was responsi-
ble for the simultaneous decrease of LDL-C level and
Lp-PLA2 activity. Similary, Tsimihodimos et al. [56]
found reduced Lp-PLA2 activity in plasma of hypercho-
lesterolemic patients under atorvastatin therapy, with a
reduction in LDL-Lp-PLA2 activity; in contrast, there
was no modification in HDL-Lp-PLA2 activity. The
same authors, in an investigation of the effect of fenofi-
brate on hypercholesterolemic patients, observed a
reduction in the LDL-Lp-PLA2 activity and an increase
of the HDL-Lp-PLA2 activity [69]. Schaefer et al. [70],
comparing the effect of atorvastatin with placebo in cor-
onary heart disease patients observed a reduction of Lp-
PLA2 under therapy.
Studying the effect of cholesterol feeding and simvas-
tatin treatment on rabbits, Zhang et al. [71] found that
the LDL-Lp-PLA2 activity increased with cholesterol
feeding and decreased after the treatment. In this way,
O’Donoghue et al. [72] found that an intensive statin
therapy was responsible for 20% of reduction in LDL-
Lp-PLA2 , in average. Likewise, Schaefer et al. [70]
observed that simvastatin determined a reduction of the
Lp-PLA2 mass in 26%.
In the same way, atorvastatin or fenofibrate therapies
can increase the ratio of HDL-Lp-PLA2 to plasma Lp-
PLA2 (or to LDL-Lp-PLA2 ) [57]. Also, the effect of
gemfibrozil was monitored in men with low HDL-C,
and it was verified that individuals in highest quartile of
Lp-PLA2 showed reduction of cardiovascular events
[73]. The use of darapladib (oral Lp-PLA2 inhibitor) by
coronary patients caused a reduction of 59% of the
enzyme activity after 12 months of treatment; concomi-
tantly, the placebo group presented a significant increase
of necrotic core volume when compared to the therapy
group [74]. In a complementary study, the combined
effect of atorvastatin and darapladib was evaluated in
patients with coronary heart disease in the course of 12
weeks; the individuals under darapladib showed a reduc-
tion of approximately 54% in the Lp-PLA2 activity when
compared with controls [75].
Investigating patients under low-fat-diet and orlistat
treatment, fenofibrate or both drugs during six months,
Filippatos et al. [76] observed a significant reduction of
Table 1 Potential action of the Lp-PLA2 , according to
studies with distinct design.
Study
design
Action Reference
Experimental Cells ROS protection. [33]
Experimental ↓ bioactivity phospholipids in oxLDL [37]
Experimental ↓ oxidized phospholipids in mildly oxLDL [38]
Case/Control ≈ Oxidized phospholipids and anti-Lp-PLA2 [41]
Case/Control ↓ HDL oxidation, foam cell and
autoantibodies titers.
[42]
Case/Control ↓ HDL-Lp-PLA2 activity [25]
Case/Control ↓ HDL-Lp-PLA2 activity [60]
Case/Control ↑ LDL-Lp-PLA2 to HDL-Lp-PLA2 ratio [31]
Case/Control ↓ HDL-Lp-PLA2 and ↑ of LDL-Lp-PLA2 [56]
Case/Control ≈ Lp-PLA2 activity [55]
Case/Control ↑ Lp-PLA2 activity [61]
Cohort ↑ Lp-PLA2 activity in CHD mortality [62]
Case/Control ↑ Lp-PLA2 activity [63]
Cohort Predictor of cardiovascular outcomes [4]
Cohort Lp-PLA2 correlated with cardiovascular risk
factors
[64]
Cohort Lp-PLA2 activity associated with MS and CVD [5]
Cohort Lp-PLA2 mass and activity associated with
CVD
[65]
Cohort ↑ Lp-PLA2 activity associated with CVD [6]
Meta-
analysis
Lp-PLA2 mass and activity associated vascular
risk
[66]
CVD: Cardiovascular Disease; CHD: Coronary Heart Disease; PAD: Peripheral
Arterial Disease; ROS: Reactive Oxygen Species, MS: Metabolic Syndrome
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Lp-PLA2 activity in all groups (14%, 22% and 35%,
respectively) when compared to basal time. The results
suggested the combination of the two treatments as the
optimal therapy.
Hence, the direct influence of lipid metabolism on Lp-
PLA2 was confirmed by the efficiency of hypocholestero-
lemic drugs. Nonetheless, a similar profile was not
observed in patients under anti-hypertension treatment:
Spirou et al. [77] and Rizos et al. [78] verified that anti-
hypertensive was not able to change Lp-PLA2 activity.
Despite the positive effect on Lp-PLA2 demonstrated
by application of drugs, many studies have also investi-
gated the influence of diet and other environment factors
on the enzyme. In this context, Pedersen et al. [79] com-
pared the effects of high (6.6 g), low (2.0 g) and control
doses of n-3 polyunsaturated fatty acids in some meta-
bolic parameters; they did not observe any effect on Lp-
PLA2 activity. Recently, in a sub-sample (n = 150, follow
up = 1 y) of PREDIMED study, the authors of the present
work, comparing diets enhanced with a mix of nuts (30
g/d), olive oil (50 g/d) or with low concentration of satu-
rated fat (< 7%), observed a reduction in Lp-PLA2 only in
the nuts group [NRTD, personal communication].
The effect of selenium on Lp-PLA2 was recently evalu-
ated [80] on rats, subject to three different diets (con-
trol, high fat and high fat enhanced with selenium). The
results showed that the Lp-PLA2 levels in control group
were lower than the other groups, and that the selenium
did not affect this enzyme.
The Nurses’ Health Study demonstrated that the
replacement of energy from carbohydrates for proteins,
as well as the alcohol consumption or use of choles-
terol-lowering drugs, were associated with a reduction
in the Lp-PLA2 activity. Smoking, overweight, aspirin
use, hypercholesterolemia and age were, nevertheless,
related to the elevation of Lp-PLA2 activity [81]. In addi-
tion, obese and non-diabetic women submitted to a
weight reduction program showed a significant reduc-
tion in Lp-PLA2 activity, directly associated with VLDL-
C [82]. The influence of the nutritional status on Lp-
PLA2 activity was also evaluated in adolescents where it
was positively associated with body mass index, waist
circumference and fat mass percentage [83].
Finally, Chen et al. [84] compared vegetarians with
omnivores and observed that vegetarians presented
lower Lp-PLA2 activity, with lower total cholesterol and
LDL-cholesterol, but with increased chances of higher
C-reactive protein.
7. Conclusion
Initially, the discovery of the enzyme Lp-PLA2 was asso-
ciated with its ability to hydrolyze PAF and phospholi-
pids, what was seen as a protective function. The
enzyme acts as an antioxidant in the presence of
oxidized phospholipids. Thus, Lp-PLA2 , in this sense,
represents an important factor, reducing the oxLDL
atherogenicity. Nowadays, however, its association with
cardiovascular events is the most outstanding character-
istic observed.
In addition, associations with several cardiovascular
risk markers were also described in the literature. The
enzyme hydrolyzes bioactive lipids, reducing their biolo-
gical activity; the major metabolites generated in the
process are the lysophospholipids. Given these results,
the enzyme has been associated with a pro-inflammatory
action, explained mainly by the production of these
compounds that stimulate the inflammatory process in
the region of the atherosclerotic plate.
Focusing on the enzyme antiatherogenic function, sev-
eral studies have been evaluating the distribution of Lp-
PLA2 in the lipid fractions. Surprisingly, the HDL-Lp-
PLA2 enzyme has proven beneficial results to the ather-
osclerotic process. In the same sense, LDL-Lp-PLA2 is
linked to higher cardiovascular risk. Drugs and diet
components that alter the lipid profile, the insulin resis-
tance and the inflammatory markers also affect the
enzyme activity and its concentration. Possibly, the
effects of these components on the Lp-PLA2 activity,
according to the lipid fraction, represent a new kind of
prevention of CVD.
The traditional assessment of cardiovascular risk is
based on lipid profile, inflammation and body composi-
tion. Since the control of these variables seeks to reduce
cardiovascular events and this enzyme is strongly related
to them, it is probable that the monitoring of its activity
and its distribution on lipoproteins will predict better
the cardiovascular risk.
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